Linking Hunan to the World: Hunan Warrant Presents Flagship APIs at CPHI Frankfurt 2025

By HWC Pharma | Updated: 2025-11-14 11:02:43

      After three dynamic days at CPHI Europe 2025—the world’s leading pharmaceutical sourcing event—Hunan Warrant stood out among global industry leaders with an impressive showcase in Frankfurt, Germany. As a key pharmaceutical manufacturer from Hunan, Warrant captivated the international stage with a specially designed booth featuring a selection of high-value APIs, drawing strong interest from over 150 pharmaceutical companies across the globe.

CPHI serves as the ultimate barometer for global pharmaceutical trends, and this year’s exhibition gathered more than 62,000 professionals and 2,400 exhibitors from 166 countries. It was the ideal platform for innovation exchange and worldwide partnership building.

At the heart of this global convergence, Hunan Warrant made a powerful statement with a custom-built 30+ square booth. The display vividly illustrated the company’s deep expertise in pharmaceutical R&D and manufacturing, along with its exciting vision for future growth.

Warrant’s exhibition team received widespread recognition from clients across Europe, South America, Southeast Asia, the Middle East, and North Africa. Visitors applauded the company’s pragmatic approach, diverse product portfolio, strong R&D capacity, and end-to-end service solutions. The high-level engagements during the event have paved the way for new orders and expanded global reach—further strengthening Warrant’s role in bringing Hunan’s pharmaceutical innovation to the world.

    With a robust portfolio of over 70 high-end APIs, Warrant continues to build its international presence. Three of its key products: Choline Alfoscerate, Ticagrelor and Tofacitinib Citrate are already approved in South Korea, while Fosfomycin Trometamol holds certifications in multiple countries. In addition, the company supplies dozens of API intermediates and more than 20 pharmaceutical excipients, reinforcing its integrated supply chain capabilities.